Your browser doesn't support javascript.
loading
Si-Ni-San ameliorates cholestatic liver injury by favoring P. goldsteinii colonization.
Li, Fanghong; Han, Qi; Cai, Yajie; Li, Yufei; Yang, Yang; Li, Jianan; Wu, Ruiyu; Chen, Ranyun; Liu, Runping.
Afiliación
  • Li F; School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, 100029, China.
  • Han Q; School of Life Sciences, Beijing University of Chinese Medicine, Beijing, 100029, China.
  • Cai Y; School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, 100029, China.
  • Li Y; School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, 100029, China.
  • Yang Y; School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, 100029, China.
  • Li J; School of Life Sciences, Beijing University of Chinese Medicine, Beijing, 100029, China.
  • Wu R; School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, 100029, China.
  • Chen R; School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, 100029, China.
  • Liu R; School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, 100029, China. Electronic address: liurunping@bucm.edu.cn.
J Ethnopharmacol ; 337(Pt 1): 118804, 2024 Sep 11.
Article en En | MEDLINE | ID: mdl-39270883
ABSTRACT
ETHNOPHARMACOLOGICAL RELEVANCE Current treatment options for cholestatic liver diseases are limited, and addressing impaired intestinal barrier has emerged as a promising therapeutic approach. Si-Ni-San (SNS) is a Traditional Chinese Medicine (TCM) formula commonly utilized in the management of chronic liver diseases. Our previous studies have indicated that SNS effectively enhanced intestinal barrier function through the modulation of gut microbiota. AIM OF THE STUDY This study aims to verify the therapeutic effects of SNS on cholestatic liver injury, focusing on elucidating the underlying mechanism involving the gut-liver axis. MATERIALS AND

METHODS:

The 16s RNA gene sequencing, non-targeted metabolomics were used to investigate the effects of SNS on the gut microbiota dysbiosis. Fecal microbiota transplantation (FMT) was conducted to identify potential beneficial probiotics underlying the therapeutic effects of SNS.

RESULTS:

Our results demonstrated that SNS significantly ameliorated cholestatic liver injury induced by partial bile duct ligation (pBDL). Additionally, SNS effectively suppressed cholestasis-induced inflammation and barrier dysfunction in both the small intestine and colon. While SNS did not impact the intestinal FXR-FGF15-hepatic CYP7A1 axis, it notably improved gut microbiota dysbiosis and modulated the profile of microbial metabolites, including beneficial secondary bile acids and tryptophan derivatives. Furthermore, gut microbiota depletion experiments and FMT confirmed that the therapeutic benefits of SNS in cholestatic liver disease are dependent on gut microbiota modulation, particularly through the promotion of the growth of potential probiotic P. goldsteinii. Moreover, a synergistic improvement in cholestatic liver injury was observed with the co-administration of P. goldsteinii and SNS.

CONCLUSION:

Our study underscores that SNS effectively alleviates cholestatic liver injury by addressing gut microbiota dysbiosis and enhancing intestinal barrier function, supporting its rational clinical utilization. Furthermore, we highlight P. goldsteinii as a promising probiotic candidate for the management of cholestatic liver diseases.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Ethnopharmacol Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Irlanda

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Ethnopharmacol Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Irlanda